Source: Xconomy

Dyne: Dyne's Upsized IPO Brings In $233M for Muscle Disorders Drug R&D

Dyne Therapeutics, a company developing genetic medicines for rare muscular disorders, has raised $233 million in an IPO that topped the preclinical-stage biotech's projections. Late Wednesday, Dyne priced its offering of about 12.3 million shares at $19 each. The Waltham, MA-based biotech had previously planned to sell 10.3 million shares in the range of $16 [...]

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Joshua Brumm's photo - President & CEO of Dyne

President & CEO

Joshua Brumm

CEO Approval Rating

90/100

Dyne is a biotechnology company that develops and commercializes therapeutics for the treatment of genetic diseases. Read more